Skip to content

Clinical study of indocyanine green fluorescence imaging in the treatment of primary hepatocellular carcinoma with cirrhosis

Clinical study of preoperative TACE combined with intraoperative indocyanine green fluorescence imaging in the treatment of primary hepatocellular carcinoma with cirrhosis background

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020042
Enrollment
Unknown
Registered
2018-12-12
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatocellular carcinoma with cirrhosis background

Interventions

A:TACE adjuvant therapy was performed 2 weeks before surgery, and intraoperative indocyanine green fluorescence imaging negative imaging hepatocellular carcinoma resection was performed
B:Intraoperative indocyanine green fluorescence imaging hepatectomy was performed

Sponsors

Institute of Automation, Chinese Academy of Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Primary liver cancer was diagnosed as BCLC B/C stage (PVTT type I-III) or IIb-IIIa stage (2017 version of primary liver cancer diagnosis and treatment specifications) according to pathological diagnostic norms or clinical diagnostic criteria; (2) Cirrhosis with child-pugh A/B liver function; (3) Aged 18 to 75 years old male and female; (4) score of general physical condition ECOG: 0-2;No major organ dysfunction; (5) Able to obtain complete follow-up information, understand the status of this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) The coagulation function is seriously decreased and cannot be corrected; (2) The main portal vein was completely embolized by cancer thrombus, with less collateral vessel formation; (3) Patients with active hepatitis or severe infection who cannot be treated at the same time; (4) There was a significant decrease in WBC and platelet in peripheral blood, with WBC 2mg/dl or creatinine clearance rate < 30ml/min; (6) Dysplasmic fluid or multiple organ failure; (7) Allergic to indocyanine green, doxorubicin, LPT and iodized oil; (8) The researcher believes that the subject may not be able to complete the study or comply with the requirements of the study (for management reasons or other reasons).

Design outcomes

Primary

MeasureTime frame
Overall survival rate;

Secondary

MeasureTime frame
Disease-free survival rate;Tumor detection rate and R0 resection rate;Liver insufficiency rate;Adverse event rate;

Countries

China

Contacts

Public ContactKun Wang

Institute of Automation, Chinese Academy of Sciences

kun.wang@ia.ac.cn+86 18612965656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026